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ttp://dx.doi.org/10.1016/j.jmoldx.2013.05.011Recent advances in modern molecular technologies allow for the examination and measurement of
cancer-related genomic changes. The number of molecular tests for evaluation of diagnostic, prognostic,
or predictive markers is expected to increase. In recent years, O6-methylguanine-DNA methyltransferase
(MGMT) promoter methylation has been ﬁrmly established as a biomarker in patients diagnosed with
gliomas, for both clinical trials and routine clinical management. Similarly, molecular markers, such as
loss of heterozygosity (LOH) for 1p/19q have already demonstrated clinical utility in treatment of
oligodendroglial tumors, and others might soon show clinical utility. Furthermore, nonrandom associa-
tions are being discovered among MGMT, 1p/19q LOH, isocitrate dehydrogenase (IDH) mutations, and
other tumor-speciﬁc modiﬁcations that could possibly enhance our ability to predict outcome and
response to therapy. While pathologists are facing new and more complicated requests for clinical
genomic testing, clinicians are challenged with increasing numbers of molecular data coming from
molecular pathology and genomic medicine. Both pathologists and oncologists need to understand the
clinical utility of molecular tests and test results, including issues of turnaround time, and their impact on
the application of targeted treatment regimens. This review summarizes the existing data that support
the rationale for MGMT promoter methylation testing and possibly other molecular testing in clinically
deﬁned glioma subtypes. Various molecular testing platforms for evaluation of MGMT methylation status
are also discussed. (J Mol Diagn 2013, 15: 539e555; http://dx.doi.org/10.1016/j.jmoldx.2013.05.011)See next page for support and disclosure information.Gliomas
Gliomas encompass a molecularly heterogeneous group of
primary brain tumors arising from glial cells. Astrocytomas
and oligodendrogliomas are the most common subtypes.1
These can be further characterized as low-grade gliomasstigative Pathology
.[WorldHealthOrganization (WHO) grades I and II] and high-
grade gliomas (WHO grades III and IV). Clinical presenta-
tions, treatments, and outcome vary according to histology
and grade.
Cankovic et alIn adult populations, low-grade glioma (LGG) generally
refers to WHO grade II gliomas, such as diffuse astrocy-
tomas, oligodendrogliomas, and oligoastrocytomas, because
WHO grade I tumors are rarely seen in adults. Approximately
2000 to 3000 LGGs are diagnosed in the United States every
year, with a peak incidence between the ages of 35 and 44
years.1,2 Although LGGs are slow growing, they demonstrate
an invasive phenotype and are associated with considerable
morbidity and mortality. Seizure is the most common pre-
senting symptom,3 but patients may present with a variety of
other symptoms, including focal neurological deﬁcits and
headaches. Magnetic resonance imaging is the imaging
modality of choice for all glioma subtypes. LGGs typically
appear as nonenhancing T2-hyperintense lesions with mass
effect. Prognosis depends on several factors.2 One scoring
system separates LGG into low-risk and high-risk groups
according to ﬁve risk factors: age (<40 versus 40 years),
tumor diameter (<6 versus 6 cm), tumor crossing the
midline (no versus yes), histology (astrocytoma versus oli-
godendroglioma or mixed glioma), and neurological deﬁcits
(absent versus present).3 The low-risk group (score of 0 to 2)
had a median overall survival (OS) of 7.72 to 7.80 years; the
high-risk group (score of 3 to 5) had a median OS of 3.20 to
3.67 years. Even though some patients may enjoy relatively
longer survival times, almost all cases of LGG eventually
progress to a higher grade.
High-grade gliomas are the most common malignant
primary brain tumors in adults in the United States, and the
incidence rate of glioblastoma (GBM) is 3.20 per 100,000
person-years.1 GBMs are associated with poor prognosis. The
median survival is only 12 to 18 months for WHO grade IV
gliomas and 2 to 5 years for WHO grade III gliomas.4 GBMs,
which account for approximately 60% to 70% of high-grade
gliomas, may present de novo (primary GBMs) or may arise
from a lower-grade glioma (secondary GBMs). Median age at
diagnosis is 64 years for GBMs and 45 years for anaplastic
gliomas.4 The only well-established risk factor for high-grade
glioma is ionizing radiation.4 Clinical signs and symptoms
depend on tumor location andmay include headaches, seizure,
focal neurological deﬁcits, and mental status changes.
Magnetic resonance imaging typically demonstrates a hetero-
geneously enhancing mass with surrounding edema and mass
effect.
Treatment options for astrocytomas and oligodendrog-
liomas, regardless of grade, include surgery, radiation therapy,Supported by the Association for Molecular Pathology.
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540and/or chemotherapy. The inﬂuence of extent of resection in
hemispheric gliomas on survival is unclear, although retro-
spective studies suggest that more aggressive resection is
associated with longer OS.5
For newly diagnosed GBM, a multicenter, randomized,
phase III clinical trial conducted by the European Organiza-
tion for Research and Treatment of Cancer (EORTC) and the
National Cancer Institute of Canada (NCIC) established
radiation therapy with concomitant and adjuvant temozolo-
mide (TMZ) as standard therapy.6 TMZ is an oral chemo-
therapeutic drug whose antitumor effect is primarily due to
alkylation (methylation) at the O6 and N7 positions of
guanine, resulting in inhibition of DNA replication. Since the
introduction of TMZ, however, it has become clear that not
all patients beneﬁt to the same extent. Given the differences in
survival beneﬁt for patients receiving TMZ, numerous
studies have attempted to identify biomarkers that can predict
outcome and response to this agent, with and without radia-
tion therapy, particularly in high-grade gliomas.
For recurrent GBM, bevacizumab, a humanized mono-
clonal antibody against vascular endothelial growth factor
(VEGF) that interferes with the growth and maintenance of
tumor blood vessels, received accelerated approval by the U.S.
Federal Drug Administration (FDA) in May 2009 (http://
www.fda.gov/AboutFDA/CentersOfﬁces/OfﬁceofMedical
ProductsandTobacco/CDER/ucm149364.htm, last accessed
July 16, 2013). Studies of bevacizumab in recurrent GBM
have demonstrated dramatically improved response rates and
6-month progression-free survival (PFS),7,8 compared with
historical controls.9 Nonetheless, GBMs invariably progress
despite the antiangiogenic therapy.
Optimal regimens for WHO grade II and III gliomas are
less well established. After surgery, treatment options may
include watchful waiting, radiation therapy, and/or chemo-
therapy, depending on histology, age, and clinical perfor-
mance status. For LGG patients, radiation therapy has
demonstrated improvements in PFS, but with similar OS,
irrespective of whether radiation therapy is given early after
surgery or delayed until the time of progression.10 TMZ has
demonstrated activity in LGG, but whether TMZ can
substitute for radiation therapy is unknown.2 For anaplastic
gliomas, the randomized, phase III NOA-04 study revealed
that initial radiation therapy and initial chemotherapy yielded
similar median time to treatment failure and similar OS.11
There were also no differences with respect to OS between
patients receiving TMZ and patients receiving PCV [pro-
carbazine, lomustine (CCNU), vincristine] chemotherapy.
Anaplastic oligodendrogliomas and anaplastic oligoas-
trocytomas are generally more responsive to treatment than
anaplastic astrocytomas,4 particularly if they carry loss of 1p
and 19q. In two large randomized phase III clinical trials in
newly diagnosed anaplastic oligodendroglial tumors, the
addition of PCV chemotherapy to radiation therapy improved
median PFS but did not prolong OS.12,13 These studies also
revealed that 1p and 19q codeletions conferred better median
PFS and OS.14,15 Treatment studies in LGGs and anaplasticjmd.amjpathol.org - The Journal of Molecular Diagnostics
MGMT Methylation in Gliomasgliomas, including studies combining radiation therapy
and TMZ, are ongoing (http://www.clinicaltrials.gov, last
accessed July 16, 2013).
Molecular Markers Other than MGMT in Gliomas
When it comes to clinical relevance of molecular markers in
LGGs, it has proven difﬁcult to distinguish prognostic
signiﬁcance (deﬁned as overall better outcome irrespective
of management) from predictive signiﬁcance (deﬁned as
better outcome when a speciﬁc treatment is administered).
Hartmann et al16 monitored a group of 89 patients with
WHO grade II gliomas who did not receive chemotherapy
or radiation therapy after surgery for PFS and OS (or end of
follow-up). The control group consisted of 50 patients with
WHO grade II gliomas who received radiation therapy or
chemotherapy at diagnosis. Tumors were analyzed for TP53
mutations, 1p/19q codeletions, MGMT (O6-methylguanine-
DNA methyltransferase) promoter methylation, and IDH1
mutations. The study showed that none of these markers are
sensitive prognostic markers for PFS in patients with WHO
grade II gliomas treated with surgery alone. In contrast, 1p/
19q codeletion and IDH1 mutation assumed prognostic
signiﬁcance after reintervention in the surgery-alone group
and were prognostic for PFS in the group of patients who
were treated at diagnosis with radiation therapy, chemo-
therapy, or both.
Somatic mutations in the IDH1 gene [on 2q33.3, exon 4
(codon R132), mutations R132H, C, L, S, or G] encoding
cytosolic NADPþedependent isocitrate dehydrogenase have
been shown in the majority of astrocytomas, oligoden-
drogliomas, and oligoastrocytomas ofWHO grades II and III.
IDH2 [on 15q26.1, exon 4 (codon R172), mutations R172G,
M, or K] encoding mitochondrial NADPþedependent iso-
citrate dehydrogenase can also be mutated in gliomas,
although in much lower frequencies.17 Isocitrate dehydroge-
nases catalyze the oxidative decarboxylation of isocitrate to
a-ketoglutarate, andmutations inactivate enzyme activities. It
has been reported that IDH1 mutations might be linked to
improved OS but not to response to TMZ at progression after
radiation therapy in patients with low-grade astrocytomas.18
A separate study showed improved response to TMZ and
increased OS in patients with LGGs with IDH1 mutations.19
In their study of low-grade astrocytomas, Hartmann et al16
also reported better response to treatment in patients with
mutant IDH1 tumors, compared with wild-type tumors.
However, the prognostic role for IDH1 mutation in LGGs
could not be conﬁrmed in other studies.20,21
In pediatric patients, a combined assay for BRAFe
KIAA1549 fusion and for IDH1 and IDH2 mutations
provides a sensitive and highly speciﬁc approach to dis-
tinguishing the pilocytic astrocytomas from diffuse astrocy-
toma. Pilocytic astrocytomas of WHO grade I often contain
the BRAF fusion (present in >70% of tumors) and are
frequently negative for IDH1/IDH2 mutations. In contrast,
diffuse astrocytomas ofWHO grade II typically exhibit IDH1The Journal of Molecular Diagnostics - jmd.amjpathol.orgmutations (in >70% of tumors) and are frequently negative
for BRAF fusions.22
In LGGs, 1p/19q codeletion in oligodendroglial tumors
was ﬁrst associated with sensitivity to alkylating-agent
chemotherapy23 and later was associated also with sensi-
tivity to radiation therapy.24 The prevalence of 1p/19q
codeletion has been estimated at between 80% and 90% of
grade II oligodendrogliomas and between 50% and 70% of
grade III oligodendrogliomas. The mechanism of 1p/19q loss
seems to be a formation of a balanced whole-arm trans-
location involving chromosomes 1 and 19, with subsequent
loss of the derivative chromosome der(1;19)(p10;q10) and
retention of the der(1;19)(q10;p10).25,26 In most cases, dele-
tions appear to represent complete loss of the chromosome
arm. Tumors with 1p/19q codeletion frequently exhibit
classic histology and often have IDH1 and IDH2mutations.17
Loss of 1p/19q is also found in approximately 20% to 30% of
mixed glial tumors (oligoastrocytomas). Recent studies have
shown that oligodendroglial tumors with polysomy of chro-
mosomes 1 and 19 have poor survival, despite loss of 1p/
19q.27,28 On the other hand, 1p/19q loss correlates inversely
with TP53 mutations, 10q deletions, and ampliﬁcation of
EGFR. Approximately 60% of diffuse astrocytomas and 40%
of oligoastrocytomas carry a TP53 mutation, and TP53
mutation is signiﬁcantly associated with shorter survival in
multivariate analysis.20,29
In general, GBM in children has a genetic proﬁle distinct
from that of adult GBM30 including a low frequency of
EGFR ampliﬁcation, a higher frequency of microsatellite
instability due to DNA mismatch repair deﬁciency, and
differences in the frequency of TP53 mutation between
children aged less than 3 years and older children.31,32 As in
adults, available limited data suggest that pediatric GBM
patients with methylated MGMT promoter appear to beneﬁt
from TMZ, with a strong correlation between the MGMT
status and OS, independent of the treatment received.33
MGMT
The MGMT protein is encoded by a single gene located on
chromosome band 10q26.34 MGMT is a large gene (>150
kb) containing ﬁve exons, the ﬁrst of which is noncoding.35
The MGMT gene has a TATA-less, CAAT-less promoter
containing a CpG island. Transcriptional control of the
MGMT gene is mediated by the 50 regulatory region. The
promoter with maximal activity lies 50 of the gene from
953 to þ202 bp (with the transcriptional initiation site as
þ1) and consists of minimal promoter (69 to þ19),36
enhancer (þ143 to þ202),37 to which MGMT enhancer
binding protein (MEBP) binds, and several transcription
factor binding sites, such as SP1 and AP1. Transcription of
the MGMT gene appears to initiate at a single site within
a guanosine-cytosine-rich, non-TATA boxecontaining
promoter. This promoter contains a CpG island38e40 and has
been shown by in vivo footprinting analysis to contain seven
sites of DNA protein interaction, six of which surround the541
Figure 1 Schematic of the MGMT promoter region with CpG island and
the CpGs most commonly interrogated by MSP, MethyLight qMSP, and
pyrosequencing.
Cankovic et altranscription start site (three upstream and three downstream)
and are consensus binding sequences for the ubiquitous
transcription factor Spl. The seventh site of interaction lies
upstream of the 50 most Spl-like site, and represents a binding
site for a currently undeﬁned transcription factor. An eighth
site of interaction lies 30 to the Spl-like binding sites, repre-
senting an enhancer-like element.37
Expression of the MGMT gene is heavily regulated by
methylation-dependent epigenetic silencing.41 Methylation
of cytosines in CpG dinucleotides is a covalent modiﬁcation
catalyzed by DNA methyltransferases. Methylation occurs
primarily in CpG islands, which are short (typically 300 to
3000 bp) stretches of CG-rich DNA, found primarily in
promoter regions. Methylation of a promoter acts to inhibit
(silence) transcription of the associated gene by binding to
speciﬁc methylated DNA-binding proteins (eg, MeCP2,
MBD2) that form multiprotein complexes that include
acetylated histones, causing condensation of chromatin and
inability to bind RNA polymerase and transcriptional
machinery.42 Most CpG islands are associated with consti-
tutively active genes (eg, housekeeping genes) and are nor-
mally unmethylated. In cancer, however, methylation can be
globally distorted, with an overall loss of DNA methylation
but aberrant hypermethylation at speciﬁc promoters. Tumor
growth and survival can become enhanced by resultant
methylation and inactivation of tumor suppressor genes,
DNA repair genes, and proapoptotic genes.
TMZ damages DNA by methylating the oxygen at position
6 of guanine nucleotides. The resultant O6-methylguanine
adducts pairwith thymidine.35DNAmismatch repair enzymes
attempt to excise O6-methylguanine, in the process generating
single- and double-strand breaks and thus leading to apo-
ptosis. However, the DNA repair enzyme MGMT restores
the normal guanine by transferring the methyl group to a
cysteine residue of MGMT. As a result, MGMT activity
rescues the cell from the damage induced by TMZ and
thus leads to resistance to therapy. Gliomas with inactivation
of the MGMT gene are less capable of repairing DNA, which
leads to increased sensitivity to alkylating chemotherapy.
Detection of MGMT Methylation
The MGMT promoter contains a 777-bp CpG island with
97 CpG sites. The changes in methylation between an
MGMT-expressing and a nonexpressing cell line are focused
in four CpG regions, which indicates that the methylation
sites that affect gene expression are not diffusely or uniformly
distributed throughout the CpG island.38,43 Studies in
MGMT cell lines identiﬁed two highly methylated regions
in the CpG island: an upstream highly methylated region
located upstream of the transcription initiation site, including
a minimal promoter and a downstream highly methylated
region downstream of exon 1.44 The 50 portion of the
upstream highly methylated region, including the ﬁrst one
third of the CpGs in the island (CpG 1 to approximately CpG
40), was highly methylated. After that, methylation gradually542decreased toward exon 1 via minimal promoter, with
hypermethylation in some cell lines and hypomethylation in
others. The downstream highly methylated region was
generally hypermethylated, especially the enhancer spanning
CpG 85 to CpG 90 (the most heavily methylated region in the
island).
Several studies showed that methylation of CpGs located
at the ﬁrst noncoding exon and enhancer are more critical
for loss of MGMT expression. Therefore, most of the
molecular assays in clinical use are designed to interrogate
these regions (Figure 1).45,46 However, methylation of the
upstream region is suspected to play a role in gene silencing.
In a clinical setting, it is technically difﬁcult to evaluate
multiple CpGs, especially because a formalin-ﬁxed,
parafﬁn-embedded specimen is often the only type avail-
able and because each method currently in clinical use
focuses on only a few speciﬁc CpG sites. The three most
commonly used methods for detection of MGMT methyla-
tion are i) methylation-speciﬁc PCR (MSP), ii) quantitative
real-time PCR or MethyLight methylation-speciﬁc quan-
titative real-time PCR (MethyLight qMSP), and iii)
methylation-speciﬁc sequencing, including pyrosequencing
(Figures 2 and 3). These methods can be used for the analysis
of either formalin-ﬁxed, parafﬁn-embedded tissue samples
or snap-frozen tissue, and all require bisulﬁte treatment
of DNA before analysis. Methods that do not require bisul-
ﬁte conversion and that can be used in clinical setting in-
clude methylation-speciﬁc multiplex ligation-dependent probe
ampliﬁcation (MS-MLPA) and immunohistochemistry
(IHC) for MGMT protein expression.Specimen Preparation for MGMT Methylation Assays
Detection of MGMT methylation is often performed on
formalin-ﬁxed, parafﬁn-embedded tumor specimens. Because
of tumor heterogeneity, MGMT expression and promoter
methylation status may depend on the site of surgical sample
collection within a glioma specimen, and careful selection of
testing samples is therefore an essential part of the testing
protocol. A pathologist is required to evaluate available tissue
and to select a tissue block with the largest number of viablejmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 2 Detection of MGMT methylation by
MSP and MethyLight qMSP. Isolated DNA from
tumor specimen is treated with sodium bisulﬁte,
which converts unmethylated cytosine (C) into
uracil (U) but leaves methylated cytosine (mC)
unchanged. The modiﬁed DNA is used as
a template for MSP or MethyLight qMSP. MSP/
agarose gel electrophoresis demonstrates absence
of MGMT methylation in tumor 1 (only the unme-
thylated band, U, is visualized on the gel) and
presence of methylation in tumor 2 (a strong
methylated band, M, is visualized). MethyLight
qMSP shows absence of MGMT methylation in
tumor 1 (ampliﬁcation is detected only in the
housekeeping gene COL2A1 control) and presence
of MGMT methylation in tumor 2 (ampliﬁcation is
detected in both the housekeeping gene COL2A1
and MGMT ).
MGMT Methylation in Gliomastumor cells. If there are contaminating nonmalignant cells in
the tissue section, the pathologist circles areas of tumor
involvement on theH&E-stained slide, for use as a template to
guide microdissection from unstained slides. The dissection
can be performed either with a phase-contrast microscope or
with laser capturemicrodissection; however,most laboratories
perform manual microdissection without a microscope, using
the marked H&E slide as a guide.
It is also recommended that the pathologist provide an
estimate of the percentage of neoplastic cells in the area that is
used for DNA extraction, and this percentage should not fall
below the limit of detection of the assay. For example, some
laboratories require that the tissue section used for DNA
extraction contain a minimum of 50% tumor cells. Enriching
for tumor cells before testing greatly increases analytic spec-
iﬁcity. In selecting the tissue sections best suited for testing, it
is also important to avoid any areas of necrosis that might be
present within a tissue block. Excessive necrosis of tumor
tissue complicates the analysis, and the pathologist should
either mark the H&E slide so that necrotic areas are avoided
or select a different tissue block if one is available. Geno-
mic DNA can be extracted from formalin-ﬁxed, parafﬁn-
embedded tissue samples using a variety of availablemethods.
Bisulﬁte Treatment
Most of the techniques for detection of MGMT methylation
involve sodium bisulﬁte modiﬁcation of DNA that converts
unmethylated cytosine into uracil, whereas methylated cy-
tosine (mC) in aCpG island remains unchanged (Figures 2 and
3). This modiﬁed DNA is then used as template for PCR.47
The differences in sequence between methylated and unme-
thylated DNA after bisulﬁte treatment allow the designing of
PCRprimers that are speciﬁc for each type. Bisulﬁte treatment
of DNA is technically the most challenging part of methyla-
tion detection, because it leads to further DNA fragmentationThe Journal of Molecular Diagnostics - jmd.amjpathol.org(although the newest commercially available bisulﬁte con-
version kits have improved recovery of ampliﬁable DNA).
Partial conversion could also be problematic, because it leads
to false-positive results. To control appropriately for bisulﬁte
effect, methylated and unmethylated controls must be treated
in parallel with patient samples, to determine whether com-
plete conversion has occurred.
MSP
MSP, the most commonly used method, allows evaluation of
methylation status at six to nine CpG sites (Figure 1).48e52
MSP is typically performed with two primer sets: one pair
for ampliﬁcation of sequences with converted cytosine after
bisulﬁte treatment for detection of an unmethylated MGMT
and a second pair of primers for ampliﬁcation of sequences
with unconverted cytosine (mC) for detection of a methylated
MGMT. PCR products are visualized by either agarose gel
electrophoresis or capillary gel electrophoresis; the latter
requires primers to be labeled with a ﬂuorescent dye
(Figure 2A).MSP can be easily incorporated into theworkﬂow
of a molecular laboratory. When well optimized, the method
delivers mostly easy-to-interpret results, and the gel-based
detection does not require expensive equipment. One disad-
vantage, however, is that the MSP method does not include
a control for bisulﬁte conversion and so incomplete conversion
of unmethylated cytosines may be interpreted as methylation
and thus lead to false-positive results. In addition, MSP does
not allow quantitative assessment of methylation and is
frequently used with an increased number of PCR cycles,
whichmay increase the likelihoodofnonspeciﬁc ampliﬁcation.
MethyLight Assay
The MethyLight assay is a simple, quantitative real-time
PCR method to determine the methylation status of MGMT543
Figure 3 Detection of MGMT methylation by pyrosequencing. Pyrograms
demonstrate unmethylated (<20% methylation), methylated (>80%
methylation), and partially methylated (>20% and <80% of CpG islands)
MGMT.
Cankovic et alCpG islands.53,54 It uses the TaqMan PCR principle, which
requires forward and reverse primers, as well as an oligo-
meric probe that emits ﬂuorescence only after it is degraded
by the 50-30 exonuclease activity of Taq polymerase. The
MethyLight assay requires that a set of primers and a ﬂuo-
rescently labeled probe be designed complementary to the
methylated MGMT sequence. In addition, a second pair of
primers and probes is used for ampliﬁcation of a house-
keeping gene, such as collagen, type III, alpha 1 (COL2A1)
or actin, to be used as the internal reference (an ampliﬁca-
tion control) for assessing the quality and quantity of input
DNA. For the housekeeping gene, primers and probes are
designed for the region of DNA containing no CpG islands544and complementary to the bisulﬁte-converted sequence.
Such design allows control for assessing the efﬁciency of
bisulﬁte conversion and to quantitate MGMT methylation.
In addition, the MethyLight assay includes a standard
dilution curve for MGMT methylated control and house-
keeping gene to quantitate the level of methylation.
The MethyLight qMSP assay is more speciﬁc than MSP
because of the addition of an oligonucleotide probe and,
depending on the assay, the inclusion of more CpGs (12 to
14 CpGs) in the analysis (Figure 1). It is usually performed
in a closed real-time PCR system and it therefore rarely
produces false-positive results. The MethyLight protocol is
easy to implement in any clinical molecular laboratory that
has access to a real-time PCR instrument. The results are
easy to interpret, and inclusion of the standard curve gives
numeric values for copy numbers of methylated MGMT
sequences as well as for the housekeeping gene sequences.
MethyLight qMSP is most helpful when used as a semi-
quantitative assay. Use of this assay for precise quantitation
of MGMT promoter methylation is not recommended,
because the percentage of contaminating stromal cells
cannot be accurately assessed.
Methylation-Speciﬁc Sequencing Methods
Pyrosequencing
The use of pyrosequencing for the detection of MGMT
promoter methylation has been the subject of a number of
studies.46,55 This method requires bisulﬁte treatment of iso-
lated DNA and PCR ampliﬁcation with primers surrounding
the CpG island, followed by pyrosequencing (Figure 3).
It allows sequencing short DNA fragments and detecting
from 4 to 12 CpGs, depending on the assay (Figure 1).
Pyrosequencing is a DNA sequencing technique based on
sequencing by synthesis. It is catalyzed by four kinetically
well-balanced enzymes (DNA polymerase, ATP sulfurylase,
ﬁreﬂy luciferase, and apyrase) in a single tube, allowing the
monitoring of DNA synthesis and enabling a rapid, real-time
sequence determination.56 The advantage of pyrosequencing
is the ability to quantify methylation at each CpG site within
the amplicon and to identify cases with low levels of meth-
ylation. Pyrosequencing is a reliable method for MGMT
promoter methylation detection. It is well suited for labora-
tories that handle large sample volumes. Because of the high
costs of the required equipment, however, pyrosequencing is
not widely used in clinical diagnostics when only small
numbers of samples are analyzed.
High-Throughput Sequencing
High-throughput proﬁling techniques, including new
sequencing methodologies and multidimensional proﬁling
from the Cancer Genome Atlas (TCGA) project, have
contributed to considerable advances in knowledge of the
molecular genetics of brain tumors.57 The large amount ofjmd.amjpathol.org - The Journal of Molecular Diagnostics
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Figure 4 MS-MLPA protocol. The MS-MLPA procedure can be divided
into four steps: i) DNA denaturation and hybridization of MLPA probes; ii)
ligation and digestion; iii) PCR and separation of ampliﬁcation products by
capillary electrophoresis; and iv) data analysis.
MGMT Methylation in Gliomasdata generated from these efforts has enabled the identiﬁ-
cation of prognostic and predictive factors and has helped to
identify pathways driving tumor growth. Currently, such
next-generation sequencing methods are still conﬁned
mostly to research laboratories; however, as the cost of
sequencing continues to decline and the methods themselves
(including data analysis) become more streamlined, these
methods will likely become available in clinical settings.
As for MSP, PCR primers can be designed to cover both the
upstream and downstream regions of CpG islands, as well as
methylated and unmethylated sequences. Standard Sanger
bidirectional DNA sequencing can then be used to provide a
semiquantitative measure of MGMT promoter methylation
status. PCRampliﬁcationand sequencingofbisulﬁte-converted
genomic DNA has emerged as the gold standard for analyzing
and comparing methylation patterns at speciﬁc loci.58
With advances in sequencing technology, genome-wide
epigenetic association studies may soon become feasible. At
present, genome-wide samples are ﬁrst enriched with target
regions by genome-partition techniques. Two leading high-
resolution, next-generation sequencing-based technologies
are Methyl-Seq and reduced representation bisulﬁte se-
quencing (RRBS). InMethyl-Seq,59 genomic DNAs from the
same biological sample are digested by the restriction endo-
nucleases MspI and HpaII. MspI cleaves all 50-CCGG-30
sites, whereas HpaII cleaves only unmethylated 50-CCGG-30
sites. The digested sites are then subject to size selection,
which acts to enrich the CpG-containing regions. Afterward,
the selected fragments are sequenced on the next-generation
sequencing platform. Sequence tags in MspI digestions
delineate assayable sites, whereas sequence tags in HpaII
digestion identify unmethylated sites speciﬁcally. In this way,
the methylation level of each site can be estimated. With
RRBS,60 a large-scale random approach for analyzing and
comparing genomicmethylation patterns, genomic DNAs are
ﬁrst enriched for CpG content by MspI digestion; the meth-
ylation status of sites is then probed by bisulﬁte sequencing.
Methylation status of a site can be inferred by comparing the
sequence tag to the reference genomic sequence.
Both Methyl-Seq and RRBS data involve methylation-
sensitive tag counts, followed by a complex process of
evaluation of methylation levels.61 Statistical issues
related to the quantiﬁcation of methylation levels by high-
throughput sequencing techniques still need to be ad-
dressed, with the goal of developing more accurate
quantiﬁcation methods.
Methods Not Requiring Bisulﬁte Conversion
MS-MLPA
MS-MLPA is a semiquantitative method that has the advan-
tage of omitting a DNA-modifying bisulﬁte treatment step
and thus avoiding additional damage to the sample DNA.
MS-MLPA can detect changes in both CpG methylation and
copy number of up to 40 chromosomal sequences in a singleThe Journal of Molecular Diagnostics - jmd.amjpathol.orgreaction.62,63 In MS-MLPA, the ligation of MLPA probe
oligonucleotides is combined with digestion of genomic
DNA-probe hybrid complex with methylation-sensitive
endonucleases (Figure 4). The methylation-speciﬁc probes
are designed so that the sequences detected contain a meth-
ylation-sensitive restriction site GCGC. ProbeeDNA com-
plex is ﬁrst treated with the methylation-sensitive restriction
endonuclease HhaI and then is used for PCR. If the CpG locus
being ampliﬁed is not methylated, HhaI cleaves its restriction
site, resulting in lack of PCR ampliﬁcation. If the CpG locus is
methylated, the HhaI restriction site is protected from
restriction enzyme digestion and PCR product is generated.63
Up to 45 probes can be added to each MLPA reaction.
Capillary electrophoresis is performed to identify and
quantify PCR products of the individual probes. To estab-
lish the amount of methylated sequences after hybridization
of the probe mix to the sample DNA, the sample is split; one
part is subjected to a single ligation step, whereas for the545
Cankovic et alother part ligation is combined with the methylation-sensitive
digestion. Subsequent PCR ampliﬁcation exponentially
ampliﬁes either total DNA or the methylated fraction only.
Comparing the peak signals of the ligated fraction and the
fraction that is also digested with HhaI generates the meth-
ylation ratios. Furthermore, comparing peak signals of the
ligated fraction with undigested control DNA evaluated in
parallel provides information about the copy number of the
evaluated probes.64 MS-MLPA can detect MGMT methyla-
tion at the key CpG sites without the need for bisulﬁte
conversion of DNA. The method is semiquantitative, so the
level of methylation at each site can also be determined. The
weaknesses of the MS-MLPA method are that analysis is
limited by the availability of restriction sites within the
fragment of interest, as well as by the need for special
equipment and expensive reagents. Additionally, incomplete
digestion leads to false-positive results.
IHC for Detection of MGMT Methylation
The use of IHC for the detection of MGMT has been
described in a number of studies, with signiﬁcant discordance
between MGMT expression as detected by IHC and by
MGMT DNA methylation, as well as discordance for
survival. In one of the earlier studies, using a mouse anti-
MGMT monoclonal antibody (Novus Molecular N99200;
MilliporeeChemicon, Temecula, CA) at 1:100 dilution and
standard immunoperoxidase staining performed on a Tech-
Mate 1000 automatic staining system (Biotek Solutions;
Ventana Medical Systems, Tucson, AZ), a mutually exclu-
sive presence of methylation or expression was shown in
a small series of eight human primary gliomas.45 Subsequent
studies either showed only a partial correlation between
methylation and expression64e66 or showed no correlation at
all.67,68 In a study of anaplastic gliomas, there was a corre-
lation between MGMT protein expression and survival, but
not between MGMT DNA methylation and survival.67 The
most important conclusion derived from these studies is that
MGMT DNA methylation and MGMT protein expression by
IHC cannot be used interchangeably to predict survival for
patients with malignant gliomas.65 This discordance may be
due in part to the fact that a correlation between MGMT
mRNA levels and protein levels can be dramatically altered
in the presence of substrates for MGMT because MGMT
interacts with its substrates in a suicide fashion and cannot be
regenerated, with a resulting precipitous drop in the amount
of active MGMT protein in the presence of large amounts of
substrate.40 At present, therefore, IHC is not the method of
choice for the detection of MGMT methylation.Functional Role of MGMT Methylation in Gene
Silencing
Although different methods for MGMT promoter methyla-
tion detection are being used in clinical settings,69 there is546still no consensus as to which method best correlates with
patient outcome.70,71 The relationship between different sites
of promoter methylation and their effect on gene silencing is
not fully understood, and most methods in clinical practice
evaluate only a few speciﬁc sites and not the entire MGMT
promoter region. To investigate the silencing effect of CpG
island hypermethylation on MGMT gene expression, Naka-
gawachi et al44 used bisulﬁte sequencing to evaluate meth-
ylation status of the entire island in 19MGMT nonexpressing
cell lines and correlated this with MGMT expression. PCR
regions for bisulﬁte sequencing were designated as region 1
(CpG 1e24), region 2 (CpG 42e69), and region 3 (CpG
73e97). Their study showed that hypermethylation of either
the upstream highly methylated region (region 1) or the
downstream highly methylated region (region 3) repressed
the transcription signiﬁcantly. They were further able to show
that the suppression effect of the downstream highly meth-
ylated region was equivalent to that of full methylation of the
entire CpG island. DNA methylation status differed among
different MGMT cell lines. Even when the pattern of
methylation was less extensive, however, those cell lines still
had the same low levels of MGMT mRNA as heavily meth-
ylated cell lines. Thus, a DNA methylation-independent
mechanism leading to the alteration of chromatin conﬁgu-
ration and gene silencing might also be involved.
Other investigation into the functional role of CpG island
methylation in MGMT silencing focused on 54 GBMs.
Everhard et al46 used pyrosequencing to quantitate the level
of methylation of 52 different CpGs and correlated these
values with MGMT mRNA expression status. Of the CpG
sites, 35 were upstream and 17 were downstream of the
transcription start site. Overall, an 85% rate of concordance
was observed between methylation and expression. When
each CpG was analyzed separately, six CpG sites were
highly correlated with expression and two CpG regions
could be used as surrogate markers for RNA expression in
81.5% of the patients. Interestingly, no difference was found
in the level of expression among the low-expressing patients
in the level of methylation once a certain minimum of
methylation sites was achieved. Out of the 52 CPG sites
analyzed, methylation of 9% of the sites seemed to be
sufﬁcient to suppressMGMT mRNA expression. When both
methylation and expression were analyzed as qualitative
variables for each CpG alone, CpGs 228, 186, þ95,
þ113, þ135, and þ137 best correlated with expression
(81.5% to 83% concordance). With both methylation and
expression as qualitative variables, the most concordant
results were observed for CpGs 186 to 172 and CpGs
þ93 to þ153, suggesting that methylation assays targeting
these regions would show the highest level of concordance
with expression levels. The study demonstrated that MGMT
methylation correlates inversely with MGMT gene expres-
sion, but it also showed that the relationship between
methylation and expression is not absolute, because it could
be conﬁrmed in only approximately 85% of the patients.
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but expressed a low level of MGMT, such as histone
modiﬁcations.72 It is also possible that MGMT DNA
methylation plays only an indirect role in regulation of gene
expression; some patients with a methylated MGMT CpG
island nonetheless expressed high levels of MGMT.43Correlation of MGMT Promoter Methylation with
Clinical Response
Although MGMT methylation does not always reﬂect gene
expression, MGMT promoter methylation status seems to be
a robust prognostic predictor in GBM patients treated with
alkylating chemotherapy.52 Importantly, if transcriptional
repression is the main mechanism underlying the higher
chemosensitivity of MGMT-methylated tumors, ﬁndings
indicating that the relationship between methylation and
expression is 85% concordant at best46 suggest that current
protocols could overlook a considerable minority of unme-
thylated patients with low expression of MGMT who are
nonetheless potentially sensitive to treatment. Conversely,
some methylated patients with high expression of MGMT
could also be inappropriately included in treatment proto-
cols. The MSP method targets CpGs at þ118 to þ137 and
þ174 to þ195. In this study, a majority of methylated
patients, as determined by MSP, expressed low level of
MGMT (87%), and unmethylated patients were found to
express either a high or low level.46 Overall, 28% discordant
results were observed, suggesting that testing only the
downstream highly unmethylated region may not be sufﬁ-
cient to give a true measure of MGMT mRNA expression.
In a more recent study of 70 GBM patients, Shah et al73
examined cytosine-guanine (CpG) dinucleotide methylation
across the entire MGMT promoter and correlated individual
CpG site methylation patterns with mRNA expression,
protein expression, and PFS. By using high-resolution
bisulﬁte sequencing, they were able to quantify the degree
of methylation at all 97 CpG sites in the MGMT promoter.
Methylation proﬁles in GBM patients were heterogeneous
across the promoter region and also within individual areas
from the same tissue samples. Their hierarchical clustering
of methylation patterns of all 70 GBM samples identiﬁed
three major sets of CpG site clusters, which they called
regions 1, 2, and 3. Methylation of either upstream (R1 and
R2) or downstream (R3) regions resulted in transcriptional
repression and decreased protein expression. (Previously
reported assays designed in MSP74 and MethyLight75
protocols target R3.) In thus study, Shah et al73 identiﬁed
four methylation patterns, based on how many regions were
methylated. A total of 36 individual CpG sites across the
promoter were signiﬁcantly correlated with MGMT mRNA
expression, and 25 sites were signiﬁcantly correlated with
MGMT protein expression. Seventeen CpG sites were
predictive of PFS: two in R1, seven in R2, and eight in R3.
Shah et al73 further showed that the lightly methylatedThe Journal of Molecular Diagnostics - jmd.amjpathol.orggroup consisting of samples with one out of three regions
methylated was similar to the unmethylated group and
consisted of samples with high protein expression and high
mRNA expression. All nine patients in this lightly methyl-
ated group had a short PFS. The moderately methylated
group, consisting of samples with any two regions methyl-
ated, was similar to the densely methylated group, in which
all three regions were methylated. The samples in this
moderately methylated group had low mRNA expression,
no protein expression, and prolonged PFS. In their earlier
study of 70 GBMs, Everhard et al46 found that the unme-
thylated group had the highest mRNA expression, the
intermediate group had lower expression, and the methyl-
ated group had the lowest. They too found that both
upstream and downstream promoter regions appeared to
have additive effect on mRNA expression.
A study that compared ﬁve different methods of MGMT
methylation status showed different levels of correlation
between MGMT methylation status and OS in GBM
patients.76 In this study, 81 tumors were obtained from
patients with GBM subsequently treated with surgery and
radiation therapy with concomitant TMZ. MGMT promoter
methylation, as assessed by MSP, pyrosequencing, and
semiquantitative MSP was signiﬁcantly correlated with OS,
whereas MGMT expression, as measured at the RNA level
by quantitative real-time RT-PCR (qRT-PCR) and at the
protein level by IHC, showed little or no correlation with
OS.76 An ongoing clinical trial, Comparative Assessment
of Methods to Analyze MGMT as a Predictive factor of
Response to Temozolomide in Glioblastomas (sponsored
by the Center Eugene Marquis, Rennes University Hos-
pital, Rennes, France; http://www.clinicaltrials.gov/show/
NCT01345370, last accessed April 10, 2013), is expected
to provide further evidence of the value of MGMT methyla-
tion as a predictive and prognostic marker. This multicenter
national study is designed to compare IHC, MSP, Methy-
Light, pyrosequencing, and methylation-sensitive high-
resolution melting analysis in a retrospective study on 100
samples.
Most methylation-speciﬁc tests are able to discriminate
clearly methylated from clearly unmethylated cases that have
association with gene silencing, and have demonstrated
prognostic value.77 Nonetheless, there seems to be a category
of intermediate samples that are more challenging. The level
of methylation of the MGMT promoter and subsequent esti-
mates of MGMT expression and activity levels are still
a subject of debate, and the issue is confounded in the pres-
ence of nontumoral tissue.78 A particularly challenging point
for all tests evaluating promoter methylation is the deﬁnition
of a technically and clinically relevant cutoff between posi-
tive and negative test results.79 It has been suggested that
the density and pattern of MGMT methylation may lead to
underestimation of methylated alleles. This could be due
to location of primers (Supplemental Table S1) or to the
ﬁdelity requirements of the polymerase with the respective
methylation-speciﬁc primers. Sciuscio et al80 estimated that547
Cankovic et aldifﬁcult to classify subgroup of patients may comprise
approximately 5% of GBM patients. This group may contain
patients who test negative for MGMT promoter methylation
but are likely to beneﬁt from alkylating-agent therapy.CpG Island Methylator Phenotype
Cancer-speciﬁc DNA methylation changes are one of the
hallmarks of human cancer. A CpG island methylator
phenotype (CIMP) was ﬁrst reported in colorectal cancers as
cancer-speciﬁc CpG island hypermethylation of some genes
in a subset of tumors.81,82 In a study that was part of the
Cancer Genome Atlas (TCGA) project, Noushmehr et al83
proﬁled DNA methylation alterations in 272 GBM tumors
and validated their ﬁndings in a set of non-TCGA GBMs and
LGGs. In their study, CIMP tumors belonged to the proneural
subgroup, were more prevalent among lower grade gliomas,
displayed distinct copy-number alterations, and were tightly
associated with IDH1 somatic mutations. Patients with CIMP
tumors also tended to be younger at the time of diagnosis and
experienced signiﬁcantly better survival.
It has been hypothesized that MGMT promoter methyla-
tion might reﬂect global DNA methylation. The long
interspersed nuclear element-1 (LINE-1) retrotransposons
have attracted attention as global DNA methylation surro-
gates. In various cancers, such as colon and ovarian cancer,
it is thought that hypomethylation of LINE-1 is correlated
with poor prognosis.84,85 A recent study investigated the
correlations among clinical, genetic, and epigenetic proﬁles
of LINE-1 as related to other cancer-related genes in LGG
and GBM glioma patients.86 In this study of 57 LGG and
54 GBM patients, LINE-1 methylation was positively
proportional to MGMT promoter methylation. In terms of
different markers, LGG samples exhibited IDH1/2 muta-
tions most frequently (82%), followed by methylated
MGMT promoters (77%), 1p/19q codeletion (42%), and
TP53 mutations (26%), consistent with the literature. This
study further demonstrated that higher methylation levels of
LINE-1 and MGMT and 1p/19q codeletion were associated
with oligodendroglial tumors. Of these alterations, 1p/19q
codeletion was most strongly associated with prolonged OS
and PFS in both univariate and multivariate analysis of
LGGs. Higher methylation levels of LINE-1 and the MGMT
promoter were observed in LGGs than in GBMs. There was
a correlation between LINE-1 methylation and good prog-
nosis among GBMs and in LGG patients over the age of 40.MGMT Methylation Status and Clinical
Management
Glioblastoma
In GBM, studies have demonstrated that MGMT promoter
methylation has prognostic value,52,87 as well as predictive
value in patients who receive alkylating agents such as548nitrosureas48 or TMZ.52,88 Hegi et al52 examined the MGMT
status of patients treated in the EORTC/NCIC phase III
clinical trial that established TMZ in combination with radi-
ation therapy as the standard of care in newly diagnosed
GBM. Patients with methylated MGMT promoter regions
lived longer, irrespective of treatment by radiation therapy
alone or radiation therapy plus TMZ. A 5-year analysis of this
same phase III clinical trial continued to demonstrateMGMT
methylation as the strongest predictor for outcome and beneﬁt
from TMZ chemotherapy.88 More recently, preliminary
results from the Radiation therapy Oncology Group (RTOG)
0525 study, a randomized phase III clinical trial comparing
two different adjuvant TMZ dosing schedules in patients with
GBM, suggest that MGMT methylation confers beneﬁt in
terms of response, PFS, and OS.87 In addition, radiographical
pseudoprogression after radiochemotherapy in newly diag-
nosed GBM patients is signiﬁcantly correlated with MGMT
status, and therefore MGMT methylation status may be able
to predict the incidence and outcome of pseudoprogression.89
In patients with an unmethylated MGMT promotor, the
beneﬁt of adding TMZ to radiation therapy is less clear. In
the EORTC/NCIC study, there was no signiﬁcant difference
in the unmethylated subgroup between radiation therapy
alone versus radiation therapy plus TMZ in terms of median
OS or PFS.52 Longer follow-up of this same group
demonstrated that the 2-year survival rate in patients with an
unmethylated promoter treated with combined therapy was
higher than those treated with radiation therapy alone.88
This improvement in survival, especially in the tail of
long-term survivors, is often used to justify the use of TMZ
in unmethylated patients. However, it is important to note
that this ﬁnding was based on a small number of patients for
whom molecular information was available and who were
alive after more than 2 years.88
Strategies to modulate MGMT activity in patients with
unmethylated MGMT include dose-dense regimens, in
which TMZ is dosed for 21 days out of each 28-day cycle,
as opposed to the standard 5-day dosing. However, pre-
liminary results from the RTOG 0525 trial demonstrated no
statistically signiﬁcant difference in OS or PFS in unme-
thylated patients who received dose-dense versus standard
adjuvant TMZ dosing after radiation therapy and concurrent
TMZ.87 Nonetheless, because MGMT promoter methylation
is strongly correlated with survival, testing should be
offered to patients with newly diagnosed GBM for prog-
nostic information and it should be part of clinical trial
stratiﬁcation in newly diagnosed GBM. MGMT methylation
should not, however, be used as a sole determinant of
alkylating chemotherapy in standard clinical practice.
The molecular mechanisms underlying GBM recurrence,
including the role of MGMT, are less clear. Studies differ on
whether MGMT is predictive or prognostic of outcomes in
the recurrent GBM population.90 In a phase II clinical trial
of a dose-dense regimen of TMZ for recurrent GBM, no
correlation was found between MGMT status and PFS or
OS.75 That mutations in MSH6 may arise during TMZjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Studies of MGMT Methylation in LGG*
Reference Type of study* Sample sizey MGMT Test Correlation to response
Everhard et al46 Retrospective review of LGG patients treated
with up-front TMZ 200 mg/m2 per day 
5 days in 28-day cycles
68 MSP Patients with methylated MGMT had
longer median PFS (29.5 mo vs 6 mo;
P < 0.01), but response rate was
not signiﬁcantly different (P Z 0.12).
Komine et al98 Retrospective review of patients with low-grade
astrocytoma treated with various regimensz
49 MSP Methylated MGMT was associated with
shorter PFS (P Z 0.0081), but OS
was not signiﬁcantly different
(P Z 0.1152).
Kesari et al99 Retrospective analysis of MGMT status from
phase II study of protracted TMZ 75 mg/m2
per day  7 weeks on and 4 weeks off in
up-front or recurrent setting for LGG
44 (20) MSP Patients with methylated MGMT had
longer OS (P Z 0.008, log-rank),
but median PFS was not signiﬁcantly
different (P Z 0.15, log-rank).
Levin et al100 Retrospective analysis of patients with low-grade
oligodendroglioma who received up-front TMZ
200 mg/m2 per day  5 days in 28-day cycles
28 IHC Low MGMT expression was associated
with objective radiographic response
(P < 0.04).
Tosoni et al101 Prospective analysis of MGMT status in LGG
patients treated with TMZ 75 mg/m2 per
day  21 days in 28-day cycles
38 (30) MSP Methylated MGMT was associated with
longer OS (P Z 0.044), but had only
a borderline association with PFS
(NR vs 17.7 mo; P Z 0.06).
Houillier et al19 Retrospective analysis of patients with LGG who
received TMZ 200 mg/m2 per day  5 days
in 28-day cycles as ﬁrst-line postoperative
treatment or at recurrence
271 (185) MSP Methylated MGMT was associated with
longer PFS in multivariate analysis
(P Z 0.02), but not with longer OS
(P Z 0.8).
*LGG includes low-grade astrocytoma, oligodendroglioma, and oligoastrocytoma.
yTotal number of patients; if applicable, the number of patients with evaluable MGMT status is given parenthetically.
zUp-front treatment regimens included 12 surgery alone, 12 with radiation therapy, and 25 with human ﬁbroblast interferon. No patients received
chemotherapy as up-front treatment; 21 patients received alkylating chemotherapy at recurrence.
IHC, immunohistochemistry; MPR, methylation-speciﬁc PCR; NR, not reached.
MGMT Methylation in Gliomastherapy has been demonstrated both in vitro and in vivo,
which might explain resistance in tumors that initially
responded to the therapy.91e95 Thus, the value of MGMT
promoter methylation testing for patients with recurrent
GBM is unclear.
MGMT Testing in Elderly Patients
The prognostic and predictive value of MGMT in elderly
patients has recently been demonstrated in several clinical
trials.MGMT methylation status predicted improved OS and
PFS, as well as quality of life, even in patients aged 70 years
or older who had poor Karnofsky performance status and
were treated with TMZ alone for newly diagnosed GBM.95
In a randomized phase III clinical trial of radiation therapy
versus dose-dense TMZ in patients 65 years and older with
newly diagnosed GBM or anaplastic astrocytoma, MGMT
promotor methylation was associated with longer OS and
event-free survival.96 Interestingly, patients with MGMT
methylated tumors had better event-free survival if they
received TMZ alone, compared with radiation therapy
alone, whereas patients with unmethylated tumors had better
outcome with radiation therapy alone. This suggests that
MGMT status may be important for determining whether to
treat an older patient with radiation therapy or with TMZ.
Testing should therefore be offered to elderly patients withThe Journal of Molecular Diagnostics - jmd.amjpathol.orgnewly diagnosed GBM or anaplastic astrocytoma for prog-
nostic information and to help guide treatment options.
Anaplastic Gliomas
In terms of anaplastic gliomas, two recent studies suggest
that methylated MGMT is a prognostic but not a predictive
marker. The NOA-04 study randomized patients with
anaplastic glioma to radiation therapy up front, followed by
chemotherapy at recurrence, versus chemotherapy up front,
followed by radiation therapy at recurrence. Patients with
methylated MGMT experienced longer PFS, regardless of
treatment.11 Similar results were obtained from a retrospec-
tive analysis of EORTC 26951, a study in which patients with
anaplastic oligodendroglial tumors were randomized to
radiation therapy alone or to radiation therapy plus adjuvant
PCV chemotherapy.97MGMT promoter methylation strongly
correlated with 1p/19q codeletion. In both treatment arms,
patients with methylated MGMT experienced longer PFS
and OS, suggesting that MGMT is an important prognostic
factor; however, MGMT was not predictive of response to
PCV chemotherapy. MGMT promoter methylation may
therefore be offered to patients with anaplastic gliomas as
a prognostic test and should be considered for stratiﬁcation in
clinical trials, but should not be used as a sole determinant of
alkylating chemotherapy in standard clinical practice.549
Cankovic et alLow-Grade Gliomas
Less is known about the effect of MGMT methylation
on survival in LGGs, because randomized controlled trials
are lacking. The available studies of MGMT in LGG are
summarized in Table 1. Except for the study reported by
Komine et al,98 these studies suggest that methylatedMGMT
by MSP or low MGMT expression as determined by IHC
correlate with favorable outcomes.99e101 However, further
studies are needed to deﬁnitively determine whether MGMT
is prognostic and/or predictive in LGG. MGMT promoter
methylation testing is therefore not currently recommended
for LGGs.
Some molecular aberrations are linked to histological
subtypes of WHO grade II gliomas and may therefore be of
diagnostic value. For example, TP53 mutations are more
common in low-grade astrocytomas, and 1p/19q codeletions
are more common in low-grade oligodendrogliomas and
oligoastrocytomas. The clinical relevance of these changes
remains controversial.
Pediatric Gliomas
Data on the role of MGMT in pediatric populations are
sparse and evolving, mostly because of the low incidence of
pediatric high-grade gliomas but also because of methodo-
logical variability across different studies. Pediatric gliomas
with overexpression of MGMT as determined by IHC
showed decreased survival in some studies,102,103 but not in
others.104 In contrast to adult gliomas, sensitivity of pedi-
atric high-grade gliomas to TMZ is less clear. Some studies
showed that pediatric gliomas are sensitive to TMZ and
patients had improved survival.33,104 Other studies,
however, did not show response to TMZ in pediatric high-
grade glioma.103 Frequency of MGMT promoter methyla-
tion seems to vary among different studies, ranging from
16% to 77% of tumors.104,105 Although Lee et al105 did not
observe any effect of MGMT promoter methylation on
outcome, Schlosser et al104 and Donson et al33 observed
increased survival in patients with MGMT promoter meth-
ylation, ﬁndings that mimic results from adult studies. In
summary, understanding of the role of MGMT in pediatric
gliomas is evolving and will beneﬁt from multi-institutional
efforts with rigorous standardized methodology.Strategies to Overcome MGMT-Mediated
Resistance to TMZ
Given the key role of MGMT in tumor resistance, two main
strategies have been implicated in overcoming its expression.
First, MGMT inhibitors can modulate chemoresistance by
inactivating MGMT. Nevertheless, these agents, such as O6-
benzylguanine, also decrease levels of MGMT in normal
cells and increase toxicity of chemotherapy,106 and in one
study they did not induce regression of recurrent gliomas.107550Furthermore, studies have shown that O6-benzylguanine
decreases expression of MGMT only transiently, and that
tumor tissue is able to synthesize MGMT rapidly and
replenish the resource.108 MGMT inhibitors with higher
tumor speciﬁcity, such as O4-benzylfolates acting via R-
folate receptor overexpressed in tumor cells, might decrease
systemic toxicity. A second strategy is based on the fact that
alkylating agents and DNA damage can deplete MGMT. An
extended TMZ schedule resulted in increased cytotoxicity
with subsequent doses, and higher doses of TMZ seemed to
deplete MGMT faster than lower doses; however, the pro-
tracted schedule resulted in sustained reduction.109 It must be
noted that reduction of MGMT activity is measured in
peripheral blood cells, and it is not certain how far this can be
extrapolated to brain tumor cells. With higher doses of
alkylating agents, normal cells are sensitized as well. Greater
hematopoietic toxicity with profound leukopenia and lym-
phopenia can lead to opportunistic infections.110e112 It is not
known which schedule would offer the best balance between
antitumor effect and hematological toxicity. However,
as noted above, preliminary results from RTOG 0525
demonstrated no statistically signiﬁcant difference in OS in
newly diagnosed GBM patients who received dose-dense or
standard adjuvant TMZ dosing after radiation therapy and
concurrent TMZ.87 In addition, there was increased toxicity
in the dose-dense TMZ arm, mostly manifesting as lym-
phopenia and fatigue. Attempts to deplete MGMT via
increased and more frequent doses of TMZ lead to increased
adverse effects. Currently, there is no consensus on how to
overcome MGMT-mediated resistance to alkylating agents.Summary
Histological criteria for diagnosis of gliomas have been well
documented in recent years, and the ability to categorize
these tumors into prognostic groups based on molecular
biology is offering hope for customized therapy based on
different tumor subtypes. A number of studies have shown
that MGMT promoter methylation confers an OS beneﬁt,
which is most pronounced in patients who receive a
combination of alkylating chemotherapy and radiation
therapy. The MGMT methylation status of glioma patients is
routinely evaluated in many institutions and is an integral part
of clinical trials. Several different methods, with different
levels of sensitivity are used, depending on expertise and
method availability in each institution, and such disparities
might hamper reproducibility of results among different
institutions. Currently, there is no recommendation to pref-
erentially use any particular method; however, as a way to
increase assay sensitivity, both slide review by a pathologist
before testing and tumor enrichment by microdissection
are recommended. Although studies in adult GBM clearly
show correlation between MGMT promoter methylation and
response to therapy, clinical utility still needs to be determined
in LGGs and is evolving in pediatric high-grade gliomas.jmd.amjpathol.org - The Journal of Molecular Diagnostics
MGMT Methylation in GliomasAcknowledgments
We thank Drs. Iris Schrijver and Ken Aldape for their
helpful suggestions during early stages of this project.
Disclaimer
The Association for Molecular Pathology (AMP) Reports are
developed to be of assistance to laboratory and other health-
care professionals by providing guidance and recommenda-
tions for particular areas of practice. The Report should not
be considered inclusive of all proper approaches or methods,
or exclusive of others. The Report cannot guarantee any
speciﬁc outcome, nor do they establish a standard of care.
The Report is not intended to dictate the treatment of
a particular patient. Treatment decisions must be made based
on the independent judgment of health care providers and
each patient’s individual circumstances.
AMP makes no warranty, express or implied, regarding
the Report and speciﬁcally excludes any warranties of
merchantability and ﬁtness for a particular use or purpose.
AMP shall not be liable for direct, indirect, special, inci-
dental, or consequential damages related to the use of the
information contained herein.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.jmoldx.2013.05.011.
References
1. Dolecek TA, Propp JM, Stroup NE, Kruchko C: CBTRUS statistical
report: primary brain and central nervous system tumors diagnosed in the
United States in 2005e2009. Neuro Oncol 2012, 14(Suppl 5):v1ev49
2. Pouratian N, Schiff D: Management of low-grade glioma. Curr
Neurol Neurosci Rep 2010, 10:224e231
3. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R,
Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim ABMF,
European Organization for Research and Treatment of Cancer Brain
Tumor Cooperative Group; European Organization for Research and
Treatment of Cancer Radiotherapy Cooperative Group: Prognostic
factors for survival in adult patients with cerebral low-grade glioma.
J Clin Oncol 2002, 20:2076e2084
4. Wen PY, Kesari S: Malignant gliomas in adults, [Erratum appeared in
N Engl J Med 2008, 359:877]. N Engl J Med 2008, 359:492e507
5. Sanai N, Berger MS: Recent surgical management of gliomas. Adv
Exp Med Biol 2012, 746:12e25
6. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B,
Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U,
Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A,
Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European
Organisation for Research and Treatment of Cancer Brain Tumor and
Radiotherapy Groups; National Cancer Institute of Canada Clinical
Trials Group: Radiotherapy plus concomitant and adjuvant temozo-
lomide for glioblastoma. N Engl J Med 2005, 352:987e996
7. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N,
Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA:
Phase II trial of single-agent bevacizumab followed by bevacizumabThe Journal of Molecular Diagnostics - jmd.amjpathol.orgplus irinotecan at tumor progression in recurrent glioblastoma. J Clin
Oncol 2009, 27:740e745
8. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D,
Abrey LE, Yung WKA, Paleologos N, Nicholas MK, Jensen R,
Vredenburgh J, Huang J, Zheng M, Cloughesy T: Bevacizumab alone
and in combination with irinotecan in recurrent glioblastoma. J Clin
Oncol 2009, 27:4733e4740
9. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP,
Prados MD, Levin VA, Yung WKA: Outcomes and prognostic
factors in recurrent glioma patients enrolled onto phase II clinical
trials. J Clin Oncol 1999, 17:2572e2578
10. van denBentMJ,AfraD, deWitte O, BenHasselM, Schraub S,Hoang-
Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R,
Karim ABMF, EORTCRadiotherapy and Brain Tumor Groups and the
UK Medical Research Council: Long-term efﬁcacy of early versus
delayed radiotherapy for low-grade astrocytoma andoligodendroglioma
in adults: the EORTC 22845 randomised trial, [Erratum appeared in
Lancet 2006, 367:1818]. Lancet 2005, 366(9490):985e990
11. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J,
Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R,
Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD,
Ernemann U, Bamberg M, Reifenberger G, von Deimling A,
Weller M: NOA-04 randomized phase III trial of sequential radio-
chemotherapy of anaplastic glioma with procarbazine, lomustine, and
vincristine or temozolomide, [Erratum appeared in J Clin Oncol 2010,
28:708]. J Clin Oncol 2009, 27:5874e5880
12. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B,
Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M,
Curran W, Intergroup Radiation therapy Oncology Group Trial 9402:
Phase III trial of chemotherapy plus radiotherapy compared with
radiotherapy alone for pure and mixed anaplastic oligodendroglioma:
Intergroup Radiation therapy Oncology Group Trial 9402. J Clin
Oncol 2006, 24:2707e2714
13. vandenBentMJ,CarpentierAF,BrandesAA,SansonM,TaphoornMJB,
Bernsen HJJA, Freanay M, Tijssen CC, Grisold W, Sipos L, Haaxma-
Reiche H, Kros JM, van Kouwenhoven MCM, Vecht CJ, Allgeier A,
Lacombe D, Gorlia T: Adjuvant procarbazine, lomustine, and vincris-
tine improves progression-free survival but not overall survival in
newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas:
a randomized European Organisation for Research and Treatment of
Cancer phase III trial. J Clin Oncol 2006, 24:2715e2722
14. van Den Bent MJ, Hoang-Xuan K, Brandes AA, Kros JM,
Kouwenhoven MCM, Taphoorn MJB, Delattre JY, Bernsen HJJB,
Frenay M, Tijssen C, Grisold W, Sipos L, Enting RH, Dinjens WNM,
French P, Vecht CJ, Allgeier A, Lacombe DA, Gorlia T: Long-term
follow-up results of EORTC 26951: A randomized phase III study on
adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors
(AOD). J Clin Oncol 2012, 30, (Suppl; abstract 2)
15. Cairncross JG, Wang M, Shaw EG, Jenkins RB, Scheithauer BW,
Brachman D, Buckner JC, Fink KL, Souhami L, Laperriere N,
Curran WJ, Mehta MP: Chemotherapy plus radiotherapy (CT-RT)
versus RT alone for patients with anaplastic oligodendroglioma:
Long-term results of the RTOG 9402 phase III study. J Clin Oncol
2012, 30, (Suppl; abstract 2008b)
16. Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O,
Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A,
Loefﬂer M, Weller M, German Glioma Network: Molecular markers
in low-grade gliomas: predictive or prognostic? Clin Cancer Res
2011, 17:4588e4599
17. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W,
Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H,
Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE,
Vogelstein B, Bigner DD: IDH1 and IDH2 mutations in gliomas. N
Engl J Med 2009, 360:765e773
18. Dubbink HJ, Taal W, van Marion R, Kross JM, van Heuvel I,
Bromberg JE, Zonnenberg BA, Zonnenberg CBL, Postma TJ,
Gijtenbeek JMM, Boogerd W, Groenendijk FH, Smitt PAES,551
Cankovic et alDinjens WNM, van den Bent MJ: IDH1 mutations in low-grade
astrocytomas predict survival but not response to temozolomide.
Neurology 2009, 73:1792e1795
19. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J,
Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K,
Sanson M, Delattre JY: IDH1 or IDH2 mutations predict longer
survival and response to temozolomide in low-grade gliomas.
Neurology 2010, 75:1560e1566
20. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B,
Keyvani K, Sure U, Wrede K, Nakazato Y, Vital A, Mariani L,
Stawski R, Watanabe T, De Girolami U, Kleihues P, Ohgaki H:
Molecular classiﬁcation of low-grade diffuse gliomas. Am J Pathol
2010, 177:2708e2714
21. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ,
Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van
Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M: IDH1 and
IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Orga-
nization for Research and Treatment of Cancer Brain Tumor Group.
Clin Cancer Res 2010, 16:1597e1604
22. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H,
Pﬁster S, von Deimling A, Hartmann C: Combined molecular anal-
ysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from
diffuse astrocytoma. Acta Neuropathol 2009, 118:401e405
23. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM,
Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y,
Ramsay DA, Louis DN: Speciﬁc genetic predictors of chemothera-
peutic response and survival in patients with anaplastic oligoden-
drogliomas. J Natl Cancer Inst 1998, 90:1473e1479
24. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR,
Stitt L, Louis DN, Cairncross JG: Allelic loss of chromosome 1 p and
radiotherapy plus chemotherapy in patients with oligodendrogliomas.
Int J Radiat Oncol Biol Phys 2000, 48:825e830
25. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M,
Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC: A t(1;
19) (q10;p10) mediates the combined deletions of 1p and 19q and
predicts a better prognosis of patients with oligodendroglioma.
Cancer Res 2006, 66:9852e9861
26. Grifﬁn CA, Burger P, Morsberger L, Yonescu R, Swierczynski S:
Identiﬁcation of der(1;19)(q10;p10) in ﬁve oligodendrogliomas
suggests mechanism of concurrent 1p and 19q loss. J Neuropathol
Exp Neurol 2006, 65:988e994
27. Snuderl M, Eichler AF, Ligon KL, Vu QU, Silver M, Betensky RA,
Ligon AH, Wen PY, Louis DN, Iafrate AJ: Polysomy for chromosomes
1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas
with concurrent 1p/19q loss. Clin Cancer Res 2009, 15:6430e6437
28. Wiens AL, Cheng L, Bertsch EC, Johnson KA, Zhang S, Hattab EM:
Polysomy of chromosomes 1 and/or 19 is common and associated
with less favorable clinical outcome in oligodendrogliomas: ﬂuores-
cent in situ hybridization analysis of 84 consecutive cases. J Neuro-
pathol Exp Neurol 2012, 71:618e624
29. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B,
Fahey M, Schüler D, Probst-Hensch NM, Yasargil MG,
Yonekawa Y, Lütolf UM, Kleihues P, Ohgaki H: Population-based
study of incidence, survival rates, and genetic alterations of low-grade
astrocytomas and oligodendrogliomas. Acta Neuropathol 2004, 108:
49e56
30. Rickert CH, Sträter R, Kaatsch P, Wassermann H, Jürgens H,
Dockhorn-Dworniczak B, Paulus W: Pediatric high-grade astrocy-
tomas show chromosomal imbalances distinct from adult cases. Am J
Pathol 2001, 158:1525e1532
31. Alonso M, Hamelin R, Kim M, Porwancher K, Sung T, Oarhar P,
Miller DC, Newcomb EW: microsatellite instability occurs in distinct
subtypes of pediatric but not adult central nervous system tumors.
Cancer Res 2001, 61:2124e2128
32. Pollack IF, Finkelstein SD, Burnham J, Holmes EJ, Hamilton RL,
Yates AJ, Finlay JL, Sposto R, Children’s Cancer Group: Age and552TP53 mutation frequency in childhood malignant gliomas: results in
a multi-institutional cohort. Cancer Res 2001, 61:7404e7407
33. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK:
MGMT promoter methylation Correlates with survival beneﬁt and
sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood
Cancer 2007, 48:403e407
34. Natarajan AT, Vermeulen S, Darroudi F, Valentine MB, Brent TP,
Mitra S, Tano K: Chromosomal localization of human O6-
methylguanine-DNA methyltransferase (MGMT) gene by in situ
hybridization. Mutagenesis 1992, 7:83e85
35. Tano K, Shiota S, Collier J, Foote RS, Mitra S: Isolation and struc-
tural characterization of a cDNA clone encoding the human DNA
repair protein for O6-alkylguanine, [Erratum appeared in Proc Natl
Acad Sci USA 1990, 87:3253]. Proc Natl Acad Sci USA 1990, 87:
686e690
36. Harris LC, Potter PM, Tano K, Shiota S, Mitra S, Brent TP: Charac-
terization of the promoter region of the human O6-methylguanine-
DNAmethyltransferase gene. Nucleic Acids Res 1991, 16:6163e6167
37. Harris LC, Remack JS, Brent TP: Identiﬁcation of a 59 bp enhancer
located at the ﬁrst exon/intron boundary of the human O6-
methylguanine-DNA methyltransferase gene. Nucleic Acids Res
1994, 22:4614e4619
38. Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS,
Futscher BW: Methylation of discrete regions of the O6-
methylguanine DNA methyltransferase (MGMT) CpG island is asso-
ciated with heterochromatinization of the MGMT transcription start
site and silencing of the gene. Mol Cell Biol 1997, 17:5612e5619
39. Qian XC, Brent TP: Methylation hot spots in the 50 ﬂanking region
denote silencing of the O6-methylguanine-DNA methyltransferase
gene. Cancer Res 1997, 57:3672e3677
40. Pieper RO: Understanding and manipulating O6-methylguanine-DNA
methyltransferase expression. Pharmacol Ther 1997, 74:285e297
41. Costello JF, Futscher BW, Tano K, Graunke DM, Pieper RO: Graded
methylation in the promoter and body of the O6-methylguanine DNA
methyltransferase (MGMT) gene correlates with MGMT expression
in human glioma cells. J Biol Chem 1994, 269:17228e17237
42. Costello JF, Futscher BW, Kroes RA, Pieper RO: Methylation-related
chromatin structure is associated with exclusion of transcription
factors from and suppressed expression of the O-6-methylguanine
DNA methyltransferase gene in human glioma cell lines. Mol Cell
Biol 1994, 14:6515e6521
43. Pieper RO, Patel S, Ting SA, Futscher BW, Costello JF: Methylation
of CpG island transcription factor binding sites is unnecessary for
aberrant silencing of the human MGMT gene. J Biol Chem 1996,
271:13916e13924
44. Nakagawachi T, Soejima H, Urano T, Zhao W, Higashimoto K,
Satoh Y: Silencing effect of CpG island hypermethylation and
histone modiﬁcations on O6-methylguanine-DNA methyltransfer-
ase (MGMT) gene expression in human cancer. Oncogene 2003,
22:8835e8844
45. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG: Inac-
tivation of the DNA repair gene O6-methylguanine-DNA methyl-
transferase by promoter hypermethylation is a common event in
primary human neoplasia. Cancer Res 1999, 59:793e797
46. Everhard S, Tost J, El Abdalaoui H, Crinière E, Busato F, Marie Y,
Gut IG, Sanson M, Mokhtari K, Laigle-Donadey F, Hoang-Xuan K,
Delattre JY, Thillet J: Identiﬁcation of regions correlating MGMT
promoter methylation and gene expression in glioblastomas. Neuro
Oncol 2009, 11:348e356
47. Rein T, DePamphilis ML, Zorbas H: Identifying 5-methylcytosine
and related modiﬁcations in DNA genomes. Nucleic Acids Res
1998, 26:2255e2264
48. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF,
Vanaclocha V, Baylin SB, Herman JG: Inactivation of the DNA-
repair gene MGMT and the clinical response of gliomas to alkylat-
ing agents, [Erratum appeared in N Engl J Med 2000, 343:1740]. N
Engl J Med 2000, 343:1350e1354jmd.amjpathol.org - The Journal of Molecular Diagnostics
MGMT Methylation in Gliomas49. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB,
Herman JG, Belinsky SA: Predicting lung cancer by detecting aberrant
promoter methylation in sputum. Cancer Res 2000, 60:5954e5958
50. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ: A simpliﬁed
laboratory validated assay for MGMT promoter hypermethylation
analysis of glioma specimens from formalin-ﬁxed parafﬁn-embedded
tissue. Lab Invest 2007, 87:392e397
51. Everhard S, Kaloshi G, Crinière E, Benouaich-Amiel A, Lejeune J,
Marie J, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K,
Delattre JY, Thiller J: MGMT methylation: a marker of response to
temozolomide in low-grade gliomas. Ann Neurol 2006, 60:740e743
52. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N,
Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L,
Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC,
Stupp R: MGMT gene silencing and beneﬁt from temozolomide in
glioblastoma. N Engl J Med 2005, 352:997e1003
53. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C,
Shibata D, Danenberg PV, Laird PW: MethyLight: a high-throughput
assay to measure DNA methylation. Nucleic Acids Res 2000, 28:e32
54. Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ,
Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW,
Loda M, Fuchs CS: Precision and performance characteristics of
bisulﬁte conversion and real-time PCR (MethyLight) for quantitative
DNA methylation analysis. J Mol Diagn 2006, 8:209e217
55. Mikeska T, Bock C, El-Maari O, Hubner A, Ehentraut D, Schramm J,
Felsberg J, Kahl P, Büttner R, Pietsch T, Waha A: Optimization of
quantitative MGMT promoter methylation analysis using pyrose-
quencing and combined bisulfate restriction analysis. J Mol Diagn
2007, 9:368e381
56. Agah A, Aghajan M, Mashayekhi F, Amini S, Davis RW,
Plummer JD, Ronaghi M, Grifﬁn PB: A multi-enzyme model for
pyrosequencing. Nucleic Acids Res 2004, 32:e166
57. De Groot JF, Sulman EP, Aldape KD: Multigene sets for clinical
application in glioma. J Natl Compr Canc Netw 2011, 9:449e457
58. Frommer M, McDonald LE, Milalr DS, Collis CM, Watt F,
Grigg GW, Molloy PL, Paul CL: A genomic sequencing protocol that
yields a positive display of 5-methylcytosine residues in individual
DNA strands. Proc Natl Acad Sci USA 1992, 89:1827e1831
59. Brunner AL, Johnson DS, Kim SW, Valouev A, Reddy TE, Neff NF,
Anton E, Medina C, Nguyen L, Chiao E, Oyolu CB, Schroth GP,
Absher DM, Baker JC, Myers RM: Distinct DNA methylation
patterns characterize differentiated human embryonic stem cells and
developing human fetal liver. Genome Res 2009, 19:1044e1056
60. Meissner A, Gnirke A, Bell GW, Ramsahoye B, Lander ES,
Jaenisch R: Reduced representation bisulﬁte sequencing for compar-
ative high-resolution DNA methylation analysis. Nucleic Acids Res
2005, 33:5868e5877
61. Wu G, Yi N, Absher D, Zhi D: Statistical quantiﬁcation of methylation
levels by next-generation sequencing. PLoS One 2011, 6:e21034
62. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F,
Pals G: Relative quantiﬁcation of 40 nucleic acid sequences by
multiplex ligation-dependent probe ampliﬁcation. Nucleic Acids Res
2002, 30:e57
63. Nygren AOH, Ameziane N, Duarte HMB, Vijzelaar RNCP,
Waisﬁsz Q, Hess CJ, Schouten JP, Errami A: Methylation-speciﬁc
MLPA (MS-MLPA): simultaneous detection of CpG methylation and
copy number changes of up to 40 sequences. Nucleic Acids Res 2005,
33:e128
64. Jeuken JWM, Cornelissen SJB, Vriezen M, Dekkers MMG,
Errami A, Sijben A, Boots-Sprenger SHE, Vesseling P: MS-MLPA:
an attractive alternative laboratory assay for robust, reliable, and
semiquantitative detection of MGMT promoter hypermethylation in
gliomas. Lab Invest 2007, 87:1055e1065
65. Maxwell JA, Johnson SP, Quinn JA, McLendon RE, Ali-Osman F,
Friedman AH, Herndon JE 2nd, Bierau K, Bigley J, Bigner DD,
Friedman HS: Quantitative analysis of O6-alkylguanine-DNA alkyl-
transferase in malignant glioma. Mol Cancer Ther 2006, 5:2531e2539The Journal of Molecular Diagnostics - jmd.amjpathol.org66. Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G:
Frequent promoter hypermethylation and low expression of theMGMT
gene in oligodendroglial tumors. Int J Cancer 2005, 113:379e385
67. Brell M, Tor tosa A, Verger E, Gil JM, Viñolas N, Villá S, Acebes JJ,
Caral L, Pujol T, Ferrer I, Ribalta T, Graus F: Prognostic signiﬁcance
of O6-methylguanine-DNA methyltransferase determined by
promoter hypermethylation and immunohistochemical expression in
anaplastic gliomas. Clin Cancer Res 2005, 11:5167e5174
68. Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K,
Felsberg J, Reifenberger G, Tonn JC, Kretzschmar HA: Intratumoral
homogeneity of MGMT promoter hypermethylation as demonstrated
in serial stereotactic specimens from anaplastic astrocytomas and
glioblastomas. Int J Cancer 2007, 121:2458e2464
69. Håvik AB, Brandal P, Honne H, Dahlback HS, Scheie D, Hektoen M,
Meling TR, Helseth E, Heim S, Lothe RA, Lind GE: MGMT
promoter methylation in gliomaseassessment by pyrosequencing and
quantitative methylation-speciﬁc PCR. J Transl Med 2012, 10:36e49
70. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R,
Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T,
Haylock B, Walker C: Extent of MGMT promoter methylation
correlates with outcome in glioblastomas given temozolomide and
radiotherapy. Br J Cancer 2009, 101:124e131
71. SepulvedaAR, JonesD,OginoS, SamowitzW,GulleyML, EdwardsR,
Levenson V, Pratt VM, Yang B, Nafa K, Yan L, Vitazka P: CpG
methylation analysisecurrent status of clinical assays and potential
applications in molecular diagnostics. J Mol Diagn 2009, 11:266e2278
72. Zhao W, Soejima H, Higashimoto K, Nagawachi TT, Urano TT,
Kudo SS, Matsukura SS, Matsuo SS, Joh KK, Mukai TT: The
essential role of histone H3 Lys9 di-methylation and MeCP2 binding
in MGMT silencing with poor DNA methylation of the promoter
CpG island. J Biochem 2005, 137:431e440
73. Shah N, Lin B, Sibenaller Z, Ryken T, Lee H, Yoon JG, Rostad S,
Foltz G: Comprehensive analysis of MGMT promoter methylation:
correlation with MGMT expression and clinical response in GBM.
PLoS One 2011, 6:e16146
74. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L,
Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R: Clinical
trial substantiates the predictive value of O-6-methylguanine-DNA
methyltransferase promoter methylation in glioblastoma patients
treated with temozolomide. Clin Cancer Res 2004, 10:1871e1874
75. Vlassenbroeck I, Caliﬁce S, Diserens AC, Migliavacca E, Straub J, Di
Stefano I, Moreau F, Hamou MF, Renard I, Delorenzi M, Flamion B,
DiGuiseppi J, Bierau K, HegiME: Validation of real-timemethylation-
speciﬁc PCR to determine O6-methylguanine-DNA methyltransferase
gene promoter methylation in glioma. J Mol Diagn 2008, 10:332e337
76. Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromant G,
Saikali S, Etcheverry A, Hamlat A, Loussouarn D, Campion L,
CamponeM,Vallette FM,Gratas-Rabbia-RéC: Prognostic value ofO6-
methylguanine-DNA methyltransferase status in glioblastoma patients,
assessed by ﬁve different methods. J Neurooncol 2010, 97:311e322
77. Christians A, Hartmann C, Benner A, Meyer J, von Deimling A,
Weller M, Wick W, Weiler M: Prognostic value of three different
methods of MGMT promoter methylation analysis in a prospective
trial on newly diagnosed glioblastoma. PLoS One 2012, 7:e33449
78. Uno M, Oba-Shinjo SM, Camargo AA, Moura RP, de Aguiar PH,
Cabrera HN, Begnami M, Rosemberg S, Teixeira MJ, Marie SKN:
Correlation ofMGMTpromotermethylation statuswith gene andprotein
expression levels in glioblastoma. Clinics 2011, 66:1747e1755
79. Malley DS, Hamoudi RA, Kocialkowski S, Pearson DM, Collins VP,
Ichimura K: A distinct region of the MGMT CpG island critical for
transcriptional regulation is preferentially methylated in glioblastoma
cells and xenografts. Acta Neuropathol 2011, 121:651e661
80. Sciuscio D, Diserens AC, van Dommelen K, Martinet D, Jones G,
Janzer RC, Pollo C, Hamou MF, Kaina B, Stupp R, Levivier M,
Hegi ME: Extent and patterns of MGMT promoter methylation in
glioblastoma- and respective glioblastoma-derived spheres. Clin
Cancer Res 2011, 17:255e266553
Cankovic et al81. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP:
CpG island methylator phenotype in colorectal cancer. Proc Natl
Acad Sci USA 1999, 96:8681e8686
82. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI,
Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D,
Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ,
Thibodeau SN, Jass J, Haile R, Laird PW: CpG island methylator
phenotype underlies sporadic microsatellite instability and is tightly
associated with BRAF mutation in colorectal cancer. Nat Genet 2006,
38:787e793
83. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K,
Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG,
Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L,
Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P,
Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K,
Cancer Genome Atlas Research Network: Identiﬁcation of a CpG
island methylator phenotype that deﬁnes a distinct subgroup of
glioma. Cancer Cell 2010, 17:510e522
84. Kawakami K, Matsunoki A, Kaneko M, Saito K, Watanabe G,
Minamoto T: Long interspersed nuclear element-1 hypomethylation is
a potential biomarker for the prediction of response to oral ﬂuo-
ropyrimidines in microsatellite stable and CpG island methylator
phenotype-negative colorectal cancer. Cancer Sci 2011, 102:166e174
85. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT,
Schernhammer ES, Giovannucci EL, Fuchs CS: A cohort study of
tumoral LINE-1 hypomethylation and prognosis in colon cancer.
J Natl Cancer Inst 2008, 100:1734e1738
86. Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T,
Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K,
Kinjo S, Ito M, Fujii M, Wakabayashi T: The global DNA methyl-
ation surrogate LINE-1 methylation is correlated with MGMT
promoter Methylation and is a better prognostic factor for glioma.
PLoS One 2011, 6:e23332
87. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi M, Jaeckle KA,
Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A,
Schultz CJ, Erridge SC, Brown PD, Chakravarti A, Curran WJ Jr.,
Mehta MP: RTOG 0525: A randomized phase III trial comparing
standard adjuvant temozolomide (TMZ) with a dose-dense (dd)
schedule in newly diagnosed glioblastoma (GBM). Neuro Oncol
2011, 13(Suppl 3):iii51, (Abstract NO-46)
88. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ,
Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P,
Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K,
Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D,
Cairncross JG, Mirimanoff RO, European Organisation for Research
and Treatment of Cancer Brain Tumour and Radiation Oncology
Groups; National Cancer Institute of Canada Clinical Trials Group:
Effects of radiotherapy with concomitant and adjuvant temozolomide
versus radiotherapy alone on survival in glioblastoma in a random-
ized phase III study: 5-year analysis of the EORTC-NCIC trial.
Lancet Oncol 2009, 10:459e466
89. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G,
Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G,
Leonardi M, Spagnolli F, Ermani M: MGMT promoter methylation
status can predict the incidence and outcome of pseudoprogression
after concomitant radiotherapy in newly diagnosed glioblastoma
patients. J Clin Oncol 2008, 26:2192e2197
90. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ,
Wick W, Hegi ME: MGMT promoter methylation in malignant
gliomas: ready for personalized medicine? Nat Rev Neurol 2010, 6:
39e51
91. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V,
Franceschi E, Biscuola M, Blatt V, Crinò L, Ermani M: Temo-
zolomide 3 weeks on and 1 week off as ﬁrst-line therapy for
recurrent glioblastoma: phase II study from gruppo Italiano
cooperative di neuro-oncologia (GICNO). Br J Cancer 2006, 95:
115e116055492. Cahill DP, Codd PJ, Batchelor TT, Curry WT, Louis DN: MSH6
inactivation and emergent temozolomide resistance in human glio-
blastomas. Clin Neurosurg 2008, 55:165e171
93. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA,
Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT,
Iafrate AJ, Louis DN: Loss of the mismatch repair protein MSH6
in human glioblastomas is associated with tumor progression
during temozolomide treatment. Clin Cancer Res 2007, 13:
2038e2045
94. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape KD, Nutt CL, Louis DN:
MSH6 mutations arise in glioblastomas during temozolomide therapy
and mediate temozolomide resistance. Clin Cancer Res 2009, 15:
4622e4629
95. Gállego Pérez-Larraya J, Ducray F, Chinot O, Catry-Thomas I,
Taillandier L, Guillamo JS, Campello C, Monjour A, Cartalat-
Carel S, Barrie M, Huchet A, Beauchesne P, Matta M, Mokhtari K,
Tanguy ML, Honnorat J, Delattre JY: Temozolomide in elderly
patients with newly diagnosed glioblastoma and poor performance
status: an ANOCEF phase II trial. J Clin Oncol 2011, 29:3050e3055
96. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M,
Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J,
Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R,
Reifenberger G, Weller M, NOA-08 study Group of Neuro-oncolgy
Working Group (NOA) of German Cancer Society: Temozolomide
chemotherapy alone versus radiotherapy alone for malignant astro-
cytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet
Oncol 2012, 13:707e715
97. van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR,
Hegi M, Jeuken JW, Ibdaih A, Brandes AA, Taphoorn MJ, Frenay M,
Lacombe D, Gorlia T, Dinjens WN, Kros JM: MGMT promoter
methylation is prognostic but not predictive for outcome to adjuvant
PCV chemotherapy in anaplastic oligodendroglial tumors: a report
from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009,
27:5881e5886
98. Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T,
Fukushima T: Promoter hypermethylation of the DNA repair gene
O6-methylguanine-DNA methyltransferase is an independent
predictor of shortened progression free survival in patients with low
grade diffuse astrocytomas. Brain Pathol 2003, 13:176e184
99. Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Nacklin EA,
Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A,
Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM,
Wem PY: Phase II study of protracted daily temozolomide for low-
grade gliomas in adults. Clin Cancer Res 2009, 15:330e337
100. Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y,
Siegal T: Progressive low-grade oligodendrogliomas: response to
temozolomide and correlation between genetic proﬁle and O6-
methylguanine DNA methyltransferase protein expression. Cancer
2006, 106:1759e1765
101. Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V,
Brandes AA: Temozolomide three weeks on and one week off as ﬁrst
line therapy for patients with recurrent or progressive low grade
gliomas. J Neurooncol 2008, 89:179e185
102. Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ,
Holmes EJ, Zhou T, Finlay JL: O6-methylguanine-DNA methyl-
transferase expression strongly correlates with outcome in childhood
malignant gliomas: results from the CCG-945 cohort. J Clin Oncol
2006, 24:3431e3437
103. Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC,
Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS, Heideman RL:
Temozolomide in the treatment of high-grade gliomas in children:
a report from the Children’s Oncology Group. Neuro Oncol 2011, 13:
317e323
104. Schlosser S, Wagner S, Mühlisch J, Hasselblatt M, Gerss J,
Wolff JEA, Frühwald MC: MGMT as a potential stratiﬁcation marker
in relapsed high-grade glioma of children: the HIT-GBM experience.
Pediatr Blood Cancer 2010, 54:228e237jmd.amjpathol.org - The Journal of Molecular Diagnostics
MGMT Methylation in Gliomas105. Lee JY, Park CK, Park SH, Wang KC, Cho BK, Kim SK: MGMT
promoter gene methylation in pediatric glioblastoma: analysis using
MS-MLPA. Childs Nerv Syst 2011, 27:1877e1883
106. Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L,
Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM,
Rich JN, Sampson J, Pegg AE, Moschel RC, McLendon RE,
Provenzale JM, Stewart ES, Tourt-Uhlig S, Garcia-Turner AM,
Herndon JE 2nd, Bigner DD, Dolan ME: Phase I trial of carmustine
plus O6-benzylguanine for patients with recurrent or progressive
malignant glioma. J Clin Oncol 2000, 18:3522e3528
107. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN,
Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM,
Pegg AE, Moschel RC, McLendon RE, Provenzale JM,
Gururangan S, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD,
Friedman HS: Phase II trial of carmustine plus O(6)-benzylguanine
for patients with nitrosourea-resistant recurrent or progressive
malignant glioma. J Clin Oncol 2002, 20:2277e2283
108. Schold SC Jr., Kokkinakis DM, Chang SM, Berger MS, Hess KR,
Schiff D, Robins HI, Mehta MP, Fink KL, Davis RL, Prados MD:
O6-benzylguanine suppression of O6-alkylguanine-DNA alkyl-
transferase in anaplastic gliomas. Neuro Oncol 2004, 6:28e32The Journal of Molecular Diagnostics - jmd.amjpathol.org109. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA,
Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L,
Statkevich P, Cutler DL, Rowinsky EK: marked inactivation of O6-
alkylguanine-DNA alkyltransferase activity with protracted temozo-
lomide schedules. Br J Cancer 2003, 88:1004e1011
110. Ganière V, Christen G, Bally F, Guillou L, Pica A, de Ribaupierre S,
Stupp R: Listeria brain abscess, Pneumocystis pneumonia and
Kaposi’s sarcoma after temozolomide. Nat Clin Pract 2006, 3:
339e343
111. Stupp R, Dietrich PY, Kraljevic SO, Pica A, Maillard I, Maeder P,
Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de
Tribolet N, Mirimanoff RO, Leyvraz S: Promising survival for
patients with newly diagnosed glioblastoma multiforme treated with
concomitant radiation plus temozolomide followed by adjuvant
temozolomide. J Clin Oncol 2002, 20:1375e1382
112. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD,
Quinn C, Williams L, Foster T, Sepkowitz KA, Chapman PB:
Selective CD4þ lymphopenia in melanoma patients treated with
temozolomide: a toxicity with therapeutic implications, [Erratum
appeared in J Clin Oncol 2004, 22:2038]. J Clin Oncol 2004, 22:
610e616555
